Kuala Lumpur, January 26 (Xinhua) Malaysia’s Ministry of Health announced on the 26th that on behalf of the Malaysian government, it signed an agreement with Malaysia’s large state-owned pharmaceutical company Fama to purchase the new vaccine developed by China’s Kexing company through the latter.
According to the statement of the Ministry of health of Malaysia, health minister Azam signed the contract on behalf of the Malaysian government on the same day. The statement said that after obtaining permission from Malaysia’s pharmaceutical regulatory authorities, the vaccine from the company is expected to be supplied to Malaysia in batches from April this year.
ZULE kanain, executive director of Fama, said in a statement on the 26th that Fama is satisfied with the results of phase III clinical trial of Kexing vaccine. The phase III clinical trial of Kexing company complies with the strict standards and guidelines of the World Health Organization. The new crown vaccine is safe, effective and of high quality.
Fama signed the cooperation agreement with China Kexing company on the 12th of this month.
According to the epidemic data released by the Ministry of health of Malaysia on the 26th, as of noon of the same day, 3585 new confirmed cases had been added in the past 24 hours, with a total of 190434 confirmed cases and 700 deaths.